Issue |
BIO Web Conf.
Volume 174, 2025
2025 7th International Conference on Biotechnology and Biomedicine (ICBB 2025)
|
|
---|---|---|
Article Number | 01016 | |
Number of page(s) | 13 | |
Section | Advances in Molecular Biology and Genetic Research | |
DOI | https://doi.org/10.1051/bioconf/202517401016 | |
Published online | 12 May 2025 |
Single-Cell RNA Sequencing Reveals Immunosuppressive Mechanisms of MDSCs in Lung Cancer
School of Biomedical Engineering, University of Technology Sydney, Sydney 2000, Australia
* Corresponding author: 2595198998@qq.com
Lung cancer remains one of the leading causes of cancer-related mortality, with a five-year survival rate of approximately 9% following metastasis. The tumor microenvironment (TME) is highly immunosuppressive, facilitating immune evasion and tumor progression. Myeloid-derived suppressor cells (MDSCs) play a key role in this process by upregulating immunosuppressive genes such as ARG1, iNOS, and PD-L1. In this study, we analyzed tumor tissue samples from 200 lung cancer patients, including both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cases, using single-cell RNA sequencing (scRNA-seq) to characterize MDSC-associated gene expression. Demographic and clinical data were considered to enhance the generalizability of findings. Results showed that ARG1 overexpression depleted arginine, inhibiting T cell proliferation, while iNOS upregulation induced oxidative stress and impaired T cell receptor signaling. PD-L1 overexpression suppressed anti-tumor immunity through checkpoint inhibition. Pathway enrichment analysis indicated that these mechanisms act synergistically to drive tumor progression. While these findings highlight ARG1, iNOS, and PD-L1 as promising therapeutic targets for overcoming MDSC-mediated immunosuppression, potential challenges remain, including off- target effects and resistance mechanisms that may limit clinical efficacy. Addressing these pathways could enhance immunotherapy and mitigate drug resistance. This study provides a foundation for developing combination therapies targeting MDSCs to improve lung cancer prognosis.
© The Authors, published by EDP Sciences, 2025
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.